08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: G protein-coupled receptor 183 (GPR183; EBI2)

Musculoskeletal disease INDICATION: Osteoporosis Mouse studies suggest inhibiting GPR183 could help treat osteoporosis. In male mice, knockout of GPR183 increased bone mass compared with normal GPR183 expression. In female mouse models of age-induced and estrogen...
07:00 , May 1, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Small molecule modulators of G protein-coupled receptor 183 (GPR183; EBI2) Small molecule modulators of EBI2 could be useful for probing the function of the receptor...
07:00 , Aug 18, 2011 |  BC Innovations  |  Targets & Mechanisms

EBI2: the race is on

A trio of pharma companies are converging on an autoimmune target called EBI2 and are starting to flesh out the orphan GPCR's role in disease. GlaxoSmithKline plc kicked off the action two months ago with...
07:00 , Aug 11, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/ pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease G protein-coupled receptor 183 (GPR183; EBI2); cholesterol 25 hydroxylase (CH25H) In vitro and mouse studies suggest antagonizing EBI2 could help treat...
08:00 , Dec 4, 2008 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Acute myelogenous leukemia (AML) Cadherin-like 24 (CDH24); solute carrier family 15 (oligopeptide transporter), member 1 (SLC15A); kinase non-catalytic C-lobe domain (KIND)...